Focus:
News
-
18 November 2019
FDA approves Novartis’ Adakveo for sickle cell disease patients
The US Food and Drug Administration (FDA) has approved Novartis’ Adakveo (crizanlizumab) to mitigate the frequency of vaso-occlusive crises (VOCs), or pain crises, in sickle cell disease patients aged 16...
-
15 November 2019
Beigene receives its first FDA approval for a MCL drug
Chinese-headquartered Beigene has announced the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL), making this the first...
-
15 November 2019
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
-
15 November 2019
FDA grants priority review to tumour drug selumetinib
The US Food and Drug Administration (FDA) has awarded priority review status for AstraZeneca and MSD (Merck)’s selumetinib to treat neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PNs)...
-
15 November 2019
Bayer to invest $100m for alliance with Dewpoint Therapeutics
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
-
14 November 2019
WHO announces pilot for insulin prequalification
The World Health Organization (WHO) has launched a pilot programme for insulin prequalification to boost access to diabetes treatment.
-
14 November 2019
Boehringer-Lilly’s diabetes drug fails to receive FDA panel votes
The US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted against Boehringer Ingelheim and Eli Lilly’s diabetes drug, empagliflozin.
-
14 November 2019
Merck acquires Calporta Therapeutics for $576m
Merck (MSD) has acquired small molecule therapies developer Calporta Therapeutics for a total consideration of approximately $576m.
-
13 November 2019
US researchers launch neurohub for brain disease therapies
US researchers have launched a research network, Weill Neurohub, to develop treatments for brain and nervous system diseases and disorders.
-
13 November 2019
Skyhawk and Celgene expand alliance to identify new drug targets
Skyhawk Therapeutics has formed a second alliance with an affiliate of Celgene to identify drug targets in autoimmune diseases, oncology and immuno-oncology.